$HCAT
Health Catalyst, Inc. Stock $hcat

$hcat Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000163642224000016 Filed on February 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$74.72M	$75.08M	$295.9M
YoY Change	1.16%	8.56%	7.13%
Cost Of Revenue	$38.10M	$42.54M	$161.1M
YoY Change	1.1%	12.3%	13.43%
Gross Profit	$36.62M	$32.55M	$134.8M
YoY Change	1.22%	4.03%	0.47%
Gross Profit Margin	49.01%	43.35%	45.56%
Selling, General & Admin	$33.62M	$27.17M	$143.9M
YoY Change	-20.71%	-23.97%	-3.58%
% of Gross Profit	91.81%	83.48%	106.72%
Research & Development	$14.87M	$17.04M	$72.63M
YoY Change	-12.94%	-9.99%	-4.03%
% of Gross Profit	40.61%	52.34%	53.87%
Depreciation & Amortization	$3.300M	$10.30M	$12.60M
YoY Change	3.13%	-11.67%	13.51%
% of Gross Profit	9.01%	31.65%	9.35%
Operating Expenses	$59.02M	$54.51M	$258.7M
YoY Change	-16.26%	-17.81%	-5.29%
Operating Profit	-$22.81M	-$21.96M	-$126.9M
YoY Change	-34.66%	-37.32%	-9.36%
Interest Expense	$2.360M	$2.595M	$9.102M
YoY Change	31.62%	147.85%	-686.47%
% of Operating Profit
Other Income/Expense, Net	-$22.00K	$21.00K	$4.000K
YoY Change	-540.0%	-184.0%	-103.17%
Pretax Income	-$20.47M	-$30.17M	-$117.8M
YoY Change	-38.18%	-15.55%	-16.86%
Income Tax	$113.0K	$143.0K	$400.0K
% Of Pretax Income
Net Earnings	-$20.59M	-$30.31M	-$118.1M
YoY Change	-37.97%	-15.29%	-14.01%
Net Earnings / Revenue	-27.55%	-40.37%	-39.92%
Basic Earnings Per Share	-$0.35		-$2.09
Diluted Earnings Per Share	-$0.35	-$0.53	-$2.09
COMMON SHARES
Basic Shares Outstanding	58.56M shares	57.55M shares	56.42M shares
Diluted Shares Outstanding	58.59M shares		56.42M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$327.8M	$317.7M	$317.7M
YoY Change	-8.16%	-12.59%	-12.59%
Cash & Equivalents	$201.4M	$106.3M	$106.3M
Short-Term Investments	$126.4M	$211.5M	$211.5M
Other Short-Term Assets	$15.48M	$15.38M	$15.38M
YoY Change	-1.6%	-5.85%	-5.85%
Inventory
Prepaid Expenses
Receivables	$53.87M	$60.29M	$60.29M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$397.1M	$393.4M	$393.4M
YoY Change	-8.6%	-8.04%	-8.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.70M	$25.71M	$39.64M
YoY Change	-6.6%	-0.83%	-6.92%
Goodwill	$190.7M	$190.7M
YoY Change	2.51%	2.51%
Intangibles	$66.22M	$73.38M
YoY Change	-21.55%	-20.4%
Long-Term Investments
YoY Change
Other Assets	$4.407M	$4.742M	$4.742M
YoY Change	-8.0%	27.0%	27.0%
Total Long-Term Assets	$298.0M	$308.4M	$308.4M
YoY Change	-6.23%	-4.95%	-4.95%
TOTAL ASSETS
Total Short-Term Assets	$397.1M	$393.4M	$393.4M
Total Long-Term Assets	$298.0M	$308.4M	$308.4M
Total Assets	$695.1M	$701.8M	$701.8M
YoY Change	-7.6%	-6.71%	-6.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.697M	$6.641M	$6.641M
YoY Change	-38.36%	50.11%	50.11%
Accrued Expenses	$22.96M	$26.64M	$26.64M
YoY Change	-16.04%	15.2%	15.2%
Deferred Revenue	$63.55M	$55.75M
YoY Change	-3.57%	1.44%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$92.21M	$89.03M	$89.03M
YoY Change	-10.04%	7.91%	7.91%
LONG-TERM LIABILITIES
Long-Term Debt	$228.4M	$228.0M	$228.0M
YoY Change	0.67%	0.67%	0.67%
Other Long-Term Liabilities	$88.00K	$74.00K	$17.83M
YoY Change	-28.46%	-38.84%	-2.28%
Total Long-Term Liabilities	$228.5M	$228.1M	$245.9M
YoY Change	0.65%	0.65%	0.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$92.21M	$89.03M	$89.03M
Total Long-Term Liabilities	$228.5M	$228.1M	$245.9M
Total Liabilities	$337.9M	$334.9M	$334.9M
YoY Change	-2.67%	2.33%	2.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.138B	-$1.117B
YoY Change	10.23%	11.83%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$357.2M	$366.9M	$366.9M
YoY Change
Total Liabilities & Shareholders Equity	$695.1M	$701.8M	$701.8M
YoY Change	-7.6%	-6.71%	-6.71%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$20.59M	-$30.31M	-$118.1M
YoY Change	-37.97%	-15.29%	-14.01%
Depreciation, Depletion And Amortization	$3.300M	$10.30M	$12.60M
YoY Change	3.13%	-11.67%	13.51%
Cash From Operating Activities	$10.27M	-$19.04M	-$33.08M
YoY Change	-283.98%	28.47%	-6.21%
INVESTING ACTIVITIES
Capital Expenditures	$208.0K	$3.011M	$1.236M
YoY Change	-51.06%	-30.32%	-42.96%
Acquisitions			$11.39M
YoY Change			-59.09%
Other Investing Activities	$86.81M	$32.93M	$34.60M
YoY Change	233.41%	211.37%	-260.15%
Cash From Investing Activities	$83.98M	$29.91M	$20.29M
YoY Change	270.81%	378.15%	-152.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.808M
YoY Change			-78.46%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$863.0K	390.0K	$2.730M
YoY Change	827.96%	-38.78%	-204.48%
NET CHANGE
Cash From Operating Activities	$10.27M	-19.04M	-$33.08M
Cash From Investing Activities	$83.98M	29.91M	$20.29M
Cash From Financing Activities	$863.0K	390.0K	$2.730M
Net Change In Cash	$95.09M	11.26M	-$10.04M
YoY Change	453.93%	-242.07%	-86.95%
FREE CASH FLOW
Cash From Operating Activities	$10.27M	-$19.04M	-$33.08M
Capital Expenditures	$208.0K	$3.011M	$1.236M
Free Cash Flow	$10.06M	-$22.05M	-$34.32M
YoY Change	-267.49%	15.2%	-8.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	76559000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42223000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	48297000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	273192000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	261222000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-143650000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193227000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1600000	usd
CY2023	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	3500000	usd
CY2022	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2300000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	5700000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	4400000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	425010000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106276000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116312000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001636422
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38993
CY2023	dei	Entity Registrant Name EntityRegistrantName	HEALTH CATALYST, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3337483
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	10897 South River Front Parkway #300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South Jordan
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84095
CY2023	dei	City Area Code CityAreaCode	801
CY2023	dei	Local Phone Number LocalPhoneNumber	708-6800
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	HCAT
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	688200000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58563005	shares
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106276000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	116312000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	211452000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	247178000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	60290000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47970000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15379000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16335000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	393397000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	427795000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25712000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25928000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13927000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16658000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	73384000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	92189000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	190652000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	185982000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4742000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3734000	usd
CY2023Q4	us-gaap	Assets Assets	701814000	usd
CY2022Q4	us-gaap	Assets Assets	752286000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6641000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4424000	usd
CY2023Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	23282000	usd
CY2022Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	19691000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	55753000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	54961000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3358000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3434000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	89034000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	82510000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	228034000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	226523000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	77000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	105000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17676000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18017000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	74000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	121000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	334895000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	327276000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58295491	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58295491	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55261922	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55261922	shares
CY2023Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	1484056000	usd
CY2022Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	1424681000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1117170000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-999023000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	33000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-648000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	366919000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	425010000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	701814000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	752286000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	276236000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	241926000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	258730000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-126897000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-140005000	usd
CY2023	hcat	Interest And Other Expense Net InterestAndOtherExpenseNet	-9106000	usd
CY2022	hcat	Interest And Other Expense Net InterestAndOtherExpenseNet	1678000	usd
CY2021	hcat	Interest And Other Expense Net InterestAndOtherExpenseNet	16458000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-117791000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-141683000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-160108000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	356000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4280000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6898000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-118147000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-137403000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153210000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.09
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.56
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.23
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.09
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.63
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.23
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56418000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53722000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47495000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56418000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54080000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47495000	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-118147000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-137403000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153210000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	662000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-487000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-102000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	19000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-94000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-26000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-117466000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-137984000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-153338000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	276099000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	245180000	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	43104000	usd
CY2021	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	20083000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20350000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4837000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	65781000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153210000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-128000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	522098000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3153000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3969000	usd
CY2022	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	10052000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3006000	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	8393000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	73082000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-137403000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-581000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3588000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	950000	usd
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1808000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56645000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-118147000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	681000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	366919000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-118147000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-137403000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-153210000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	55756000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	72104000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	65145000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42223000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	48297000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37528000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	9720000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2236000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1202000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	4081000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	5023000	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1800000	usd
CY2023	hcat	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-2990000	usd
CY2022	hcat	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-3231000	usd
CY2021	hcat	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-3585000	usd
CY2023	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	1821000	usd
CY2022	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	691000	usd
CY2021	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	499000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1511000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1500000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11948000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	8000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4523000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7134000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4668000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	20036000	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	0	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	3234000	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	9085000	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	67000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-145000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-53000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13663000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-788000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-102000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-164000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	478000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4442000	usd
CY2023	hcat	Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities	4868000	usd
CY2022	hcat	Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities	-4702000	usd
CY2021	hcat	Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities	5202000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1487000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5997000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7637000	usd
CY2023	hcat	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3552000	usd
CY2022	hcat	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3518000	usd
CY2021	hcat	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3883000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33080000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35270000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23123000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	336801000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	315171000	usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	186893000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	290836000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	308961000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	261363000	usd
CY2023	hcat	Capitalized Of Internal Use Software CapitalizedOfInternalUseSoftware	11957000	usd
CY2022	hcat	Capitalized Of Internal Use Software CapitalizedOfInternalUseSoftware	12987000	usd
CY2021	hcat	Capitalized Of Internal Use Software CapitalizedOfInternalUseSoftware	6644000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	27846000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	46763000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1236000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2167000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1118000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2260000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1373000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	31000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	29000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	22000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20293000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39021000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-139678000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1808000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	950000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3969000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20350000	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1342000	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	6290000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	245180000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2730000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2613000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	264084000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-11000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10036000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-76915000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	101273000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116312000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193227000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	91954000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	5750000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	5750000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	6360000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	266000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	297000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	138000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2033000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	169000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	1310000	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	488000	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	520000	usd
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	889000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	976000	usd
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	636000	usd
CY2023	hcat	Capitalized Internal Use Software In Accounts Payable And Accrued Liabilities CapitalizedInternalUseSoftwareInAccountsPayableAndAccruedLiabilities	169000	usd
CY2022	hcat	Capitalized Internal Use Software In Accounts Payable And Accrued Liabilities CapitalizedInternalUseSoftwareInAccountsPayableAndAccruedLiabilities	448000	usd
CY2021	hcat	Capitalized Internal Use Software In Accounts Payable And Accrued Liabilities CapitalizedInternalUseSoftwareInAccountsPayableAndAccruedLiabilities	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	213000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	983000	usd
CY2023	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	0	usd
CY2022	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	10052000	usd
CY2021	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	20083000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3006000	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	43104000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, reserve for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software, impairment assessments of goodwill, intangible assets, and other long-lived assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ significantly from those estimates.</span></div>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	hcat	Revenue From Subscriptions Contract Notice Required For Termination RevenueFromSubscriptionsContractNoticeRequiredForTermination	P90D
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	4700000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	900000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	800000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	55800000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	55100000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	57600000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	2200000	usd
CY2022Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	1500000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Amortization Period CapitalizedContractCostAmortizationPeriod	P12M
CY2023Q4	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	3300000	usd
CY2022Q4	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	2600000	usd
CY2023	hcat	Commission Payment Estimated Benefit Period CommissionPaymentEstimatedBenefitPeriod	P4Y
CY2023	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	2300000	usd
CY2022	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	2100000	usd
CY2021	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	1100000	usd
CY2021	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	usd
CY2022	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	usd
CY2023	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2300000	usd
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1200000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1821000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	691000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	499000	usd
CY2023	hcat	Accounts Receivable Allowance For Credit Loss Writeoff Recovery AccountsReceivableAllowanceForCreditLossWriteoffRecovery	16000	usd
CY2022	hcat	Accounts Receivable Allowance For Credit Loss Writeoff Recovery AccountsReceivableAllowanceForCreditLossWriteoffRecovery	-9000	usd
CY2021	hcat	Accounts Receivable Allowance For Credit Loss Writeoff Recovery AccountsReceivableAllowanceForCreditLossWriteoffRecovery	99000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4105000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2300000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1600000	usd
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1400000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	2600000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to a concentration of credit risk consist principally of cash and cash equivalents, short-term investments, and accounts receivable. We deposit cash with high credit quality financial institutions which at times may exceed federally insured amounts. We have not experienced any losses on our deposits.</span></div>We perform ongoing credit evaluations of our clients’ financial condition and require no collateral from clients. We review the expected collectability of accounts receivable and record an allowance for credit losses based on the probability of future collections.
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	295938000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	276236000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	241926000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q4	us-gaap	Goodwill Goodwill	190652000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	185982000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	207493000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	134109000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	73384000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	197104000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	104915000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	92189000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29600000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37200000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	32000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	25216000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	18343000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	14491000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	11280000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2729000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1325000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	73384000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	53069000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	43385000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27357000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17457000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25712000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25928000	usd
CY2023	us-gaap	Depreciation Depreciation	12600000	usd
CY2022	us-gaap	Depreciation Depreciation	11100000	usd
CY2021	us-gaap	Depreciation Depreciation	5500000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	12800000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	14100000	usd
CY2021Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	7300000	usd
CY2023	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	8500000	usd
CY2022	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	6800000	usd
CY2021	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	2400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	311144000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	117000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	30000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	311231000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	362285000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	583000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	361710000	usd
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	900000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	600000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11680000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12180000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	2355000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	1837000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9247000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5674000	usd
CY2023Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	23282000	usd
CY2022Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	19691000	usd
CY2023Q4	hcat	Subleased Rentable Area SubleasedRentableArea	54399	sqft
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3359000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3313000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3265000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3269000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3272000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9126000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	25604000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4570000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21034000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13927000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16658000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3358000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3434000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17676000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18017000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21034000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21451000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	usd
CY2023Q4	us-gaap	Share Price SharePrice	9.26
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54079732	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47494768	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Shares Outstanding SharesOutstanding	58530880	shares
CY2023Q4	us-gaap	Shares Issued SharesIssued	58530880	shares
CY2022Q4	us-gaap	Shares Outstanding SharesOutstanding	55764942	shares
CY2022Q4	us-gaap	Shares Issued SharesIssued	55764942	shares
CY2023Q4	hcat	Stockholders Vote StockholdersVote	1	vote
CY2023	us-gaap	Dividends Cash DividendsCash	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-118147000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-137403000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-153210000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56418397	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53721702	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47494768	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.09
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.56
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.23
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-118147000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-137403000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-153210000	usd
CY2023	hcat	Change In Fair Value Of Dilutive Shares Issuable As Contingent Consideration ChangeInFairValueOfDilutiveSharesIssuableAsContingentConsideration	0	usd
CY2022	hcat	Change In Fair Value Of Dilutive Shares Issuable As Contingent Consideration ChangeInFairValueOfDilutiveSharesIssuableAsContingentConsideration	-4668000	usd
CY2021	hcat	Change In Fair Value Of Dilutive Shares Issuable As Contingent Consideration ChangeInFairValueOfDilutiveSharesIssuableAsContingentConsideration	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-118147000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142071000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-153210000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56418397	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53721702	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47494768	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	358030	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56418397	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.09
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.63
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.23
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12448289	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13594980	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7333258	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55756000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72104000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65145000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55756000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72104000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65145000	usd
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	900000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	1000000	usd
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	600000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P4Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1748306	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.51
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	690493	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	130710	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.27
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	221144	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	12.78
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1396452	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.70
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	85565	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1396452	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.70
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	85565	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1396452	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.70
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	85565	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	204000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	43000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	27000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	144000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	200000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	209000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	348000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	243000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	236000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	8000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3723000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5975000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-799000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1159000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	8000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4523000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7134000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	356000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4280000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6898000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.006
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.024
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.070
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.071
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.061
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.009
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.027
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.140
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.117
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.229
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.030
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.043
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4300000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6900000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4500000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7100000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	154938000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	151256000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	27273000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	27283000	usd
CY2023Q4	hcat	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	30745000	usd
CY2022Q4	hcat	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	16564000	usd
CY2023Q4	hcat	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	5345000	usd
CY2022Q4	hcat	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	5453000	usd
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	3167000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	6204000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1653000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3363000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	722000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	377000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1683000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1234000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4946000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1299000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1968000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	542000	usd
CY2023Q4	hcat	Deferred Tax Assets Allowance For Bad Debt DeferredTaxAssetsAllowanceForBadDebt	1028000	usd
CY2022Q4	hcat	Deferred Tax Assets Allowance For Bad Debt DeferredTaxAssetsAllowanceForBadDebt	577000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	118000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	117000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	233586000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	214269000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	226267000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	206022000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7319000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8247000	usd
CY2023Q4	hcat	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	33000	usd
CY2022Q4	hcat	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	27000	usd
CY2023Q4	hcat	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	3493000	usd
CY2022Q4	hcat	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	4183000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	2470000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	3034000	usd
CY2023Q4	hcat	Deferred Tax Liabilities Deferred Commissions DeferredTaxLiabilitiesDeferredCommissions	1323000	usd
CY2022Q4	hcat	Deferred Tax Liabilities Deferred Commissions DeferredTaxLiabilitiesDeferredCommissions	1002000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	73000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	65000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	1000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7392000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8312000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	73000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	65000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20200000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	45500000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6821000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6848000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5578000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	3000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	27000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	122000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1392000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6818000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6821000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6848000	usd
CY2023	hcat	Contract With Customer Liability Revenue Recognized Percentage ContractWithCustomerLiabilityRevenueRecognizedPercentage	0.18
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	264400000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.65
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P24M
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5700000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4900000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3800000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	295938000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	276236000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	241926000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-117791000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-141683000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-160108000	usd

Files In Submission

Name	View Source	Status
0001636422-24-000016-index-headers.html	Edgar Link	pending
0001636422-24-000016-index.html	Edgar Link	pending
0001636422-24-000016.txt	Edgar Link	pending
0001636422-24-000016-xbrl.zip	Edgar Link	pending
exhibit1013xseparationandr.htm	Edgar Link	pending
exhibit101non-employeedire.htm	Edgar Link	pending
exhibit97-policyforrecover.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hcat-20231231.htm	Edgar Link	pending
hcat-20231231.xsd	Edgar Link	pending
hcat-20231231_g1.jpg	Edgar Link	pending
hcat-20231231_g2.jpg	Edgar Link	pending
hcat-20231231_g3.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
hcat-20231231_def.xml	Edgar Link	unprocessable
hcat-20231231_lab.xml	Edgar Link	unprocessable
hcat-20231231_pre.xml	Edgar Link	unprocessable
hcat-20231231_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ye2023-10xkex211xsubsidiar.htm	Edgar Link	pending
ye2023-10xkex231xconsentof.htm	Edgar Link	pending
ye2023-10xkex311xcertifica.htm	Edgar Link	pending
ye2023-10xkex312xcertifica.htm	Edgar Link	pending
ye2023-10xkex321xcertifica.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hcat-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCAT
Health Catalyst, Inc. Stock $hcat

2024 Q1 Form 10-K Financial Statement

#000163642224000016 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCAT Health Catalyst, Inc. Stock $hcat

2024 Q1 Form 10-K Financial Statement

#000163642224000016 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCAT
Health Catalyst, Inc. Stock $hcat